Entera Bio to Participate in the Leerink Partners 2026 Global Healthcare Conference
Rhea-AI Summary
Entera Bio (NASDAQ: ENTX) announced that CEO Miranda Toledano will take part in a fireside chat at the Leerink Partners Global Healthcare Conference 2026.
The session is scheduled for March 11, 2026 at 10:40 a.m. ET in Miami; a live webcast and slides will be available, with a replay accessible for 365 days.
Positive
- None.
Negative
- None.
News Market Reaction – ENTX
In the Feb 26 session, ENTX declined 4.43%, reflecting a moderate negative market reaction. Argus tracked a trough of -10.0% from its starting point during tracking. Our momentum scanner triggered 3 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Feb 11 | Insider share purchases | Positive | +13.1% | Board members disclosed open-market purchases of company shares. |
| Feb 09 | Chairman appointment | Positive | +27.9% | Appointment of Geno J. Germano as Chairman ahead of key milestones. |
| Feb 04 | Partnership expansion | Positive | -2.4% | Expanded OPKO collaboration on long-acting PTH tablet and governance changes. |
| Jan 21 | Pipeline outlook | Positive | +0.6% | Outlined Q1 2026 priorities, including EB613 Phase 3 and EB612 plans. |
| Dec 23 | Regulatory milestone | Positive | -6.4% | FDA qualification of total hip BMD as a surrogate endpoint highlighted for EB613. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent leadership, insider buying, and strategic pipeline updates often saw positive price reactions, while partnership and broader regulatory milestone news showed occasional negative follow-through.
Over the past few months, Entera Bio has focused on leadership upgrades, insider alignment, and advancing its oral PTH pipeline. In February 2026, the company expanded its OPKO collaboration for a long-acting PTH tablet and appointed industry veteran Geno J. Germano as Chairman, both tied to upcoming Phase 3 and first-in-human studies. Multiple directors reported open-market share purchases in February 2026. Against this backdrop, the Leerink conference participation fits a pattern of heightened investor outreach during a catalyst-rich period.
AI-generated analysis. How Rhea-AI works. Not financial advice.
TEL AVIV, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) ("Entera" or the "Company"), a leader in the development of oral peptide and protein replacement therapies, today announced that the Company’s Chief Executive Officer, Miranda Toledano, will be participating in a fireside chat at the Leerink Partners Global Healthcare Conference 2026, details as below.
Leerink Partners Global Healthcare Conference 2026 (Fireside Chat and 1x1 Meetings)
Date and Time: March 11, 2026 at 10:40 a.m. Eastern Time
Location: In person, March 8–11, 2026, W South Beach, Miami, Florida
A live webcast of the discussion, including presentation slides, will be available at the link below. A replay will remain accessible for 365 days following the event.
Webcast Link: https://event.summitcast.com/view/mT9poctHDNthc6b89WqVjf/guest_book?session_id=NDXWCQc9wYa2XNNoWtMrGn
About Entera Bio
Entera is a clinical stage company focused on developing oral peptide and protein replacement therapies for significant unmet medical needs where an oral tablet form holds the potential to transform the standard of care. The Company leverages on a disruptive and proprietary technology platform (N-Tab®) and its pipeline of first-in-class oral peptide programs targeting PTH(1-34), GLP-1 and GLP-2. The Company’s most advanced product candidate, EB613 (oral PTH(1-34)), is being developed as the first oral, osteoanabolic (bone building) once-daily tablet treatment for post-menopausal women with low BMD and high-risk osteoporosis. A placebo-controlled, dose-ranging Phase 2 study of EB613 tablets (n= 161) met primary (PD/bone turnover biomarker) and secondary endpoints (BMD). The EB612 program is being developed as the first oral PTH(1-34) tablet peptide replacement therapy for hypoparathyroidism. Entera is also developing the first oral oxyntomodulin, a dual targeted GLP1/glucagon peptide, in tablet form for the treatment of obesity and metabolic syndromes; and first oral GLP-2 peptide as an injection-free alternative for patients suffering from rare malabsorption conditions such as short bowel syndrome in collaboration with OPKO Health. For more information on Entera Bio, visit www.enterabio.com or follow us on LinkedIn, Twitter, and Facebook.
Company Contact:
IR@enterabio.com
